Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Accounts Receivable : $352.4 Mil (As of Jun. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Biohaven Pharmaceutical Holding Co Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Biohaven Pharmaceutical Holding Co's accounts receivables for the quarter that ended in Jun. 2022 was $352.4 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Biohaven Pharmaceutical Holding Co's Days Sales Outstanding for the quarter that ended in Jun. 2022 was 149.53.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Biohaven Pharmaceutical Holding Co's Net-Net Working Capital per share for the quarter that ended in Jun. 2022 was $-18.51.

Biohaven Pharmaceutical Holding Co Accounts Receivable Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Accounts Receivable Chart

Biohaven Pharmaceutical Holding Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Accounts Receivable

Get a 7-Day Free Trial

120.11

308.27

Biohaven Pharmaceutical Holding Co Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Accounts Receivable	Get a 7-Day Free Trial															168.64	252.95	308.27	328.34	352.45

Biohaven Pharmaceutical Holding Co Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Biohaven Pharmaceutical Holding Co Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Biohaven Pharmaceutical Holding Co's Days Sales Outstanding for the quarter that ended in Jun. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	352.449	/	215.079	*	91
=	149.53

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Biohaven Pharmaceutical Holding Co's accounts receivable are only considered to be worth 75% of book value:

Biohaven Pharmaceutical Holding Co's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2022 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(553.486	+	0.75 * 352.449	+	0.5 * 106.561	-	2191.807
-	0	-	-4.625)	/	71.1111
=	-18.51

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Biohaven Pharmaceutical Holding Co Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510

Website

https://www.biohavenpharma.com

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

Executives

Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark	officer: VP, Chief Accounting Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic	director	215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Elyse Stock	officer: Chief Medical Officer	215 CHURCH STREET NEW HAVEN CT 06510
James Engelhart	officer: Chief Financial Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten	officer: Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Declan Doogan	director	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs	director, 10 percent owner	111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Kishan Mehta	director	540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Jones William A Jr	officer: CCO-Migraine & Common Disease	NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Kimberly Gentile	officer: VP of Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Robert Berman	officer: Chief Medical Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John Tilton	officer: Chief Commercial Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054